Literature DB >> 22561696

Association of polymorphisms of endothelial nitric oxide synthase (eNOS) gene with the risk of primary open angle glaucoma in a Brazilian population.

Thiago Magalhães da Silva1, Auta Viviane Rocha, Riccardo Lacchini, Cintia Rodrigues Marques, Elias Souza Silva, José Eduardo Tanus-Santos, Fabrício Rios-Santos.   

Abstract

The present study aimed to investigate the association of endothelial nitric oxide synthase (eNOS) gene polymorphisms with primary open angle glaucoma (POAG). We conducted a case-control study that included 90 patients with POAG and 127 healthy controls whose blood samples were genotyped for the functional polymorphisms T-786C and Glu298Asp of the eNOS gene by Taqman fluorescent allelic discrimination assay. The T-786C polymorphism was significantly associated as a risk factor for POAG among women (OR: 2.28; 95% CI: 1.11 to 4.70, p=0.024) and marginally associated to the risk of POAG in the patients ≥52 years of age at diagnosis (OR: 2.11; 95% CI: 0.98 to 4.55, p=0,055). However, these results was not confirmed after adjustments for gender, age, self-declared skin color, tobacco smoking and eNOS genotypes by multivariate logistic regression model (OR: 2.08; 95% CI: 0.87 to 5.01, p=0.101 and OR: 2.20; 95% CI: 0.95 to 5.12, p=0.067, respectively). The haplotype CG of T-786C and Glu298Asp showed a borderline association with risk of POAG in the overall analysis (OR: 1.76; 95% CI: 0.98 to 3.14, p=0.055) and among women (OR: 2.02; 95% CI: 0.98 to 4.16, p=0.052). Furthermore, the CG haplotype was significantly associated with the development of POAG for the age at diagnosis group ≥52 years (OR: 3.48; 95% CI: 1.54 to 7.84, p=0.002).We suggested that haplotypes of the polymorphisms T-786C and Glu298Asp of eNOS may interact with gender and age in modulating the risk of POAG.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22561696     DOI: 10.1016/j.gene.2012.04.047

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  24 in total

1.  Increased bioavailability of cyclic guanylate monophosphate prevents retinal ganglion cell degeneration.

Authors:  Lauren K Wareham; Ana C Dordea; Grigorij Schleifer; Vincent Yao; Annabelle Batten; Fei Fei; Joseph Mertz; Meredith Gregory-Ksander; Louis R Pasquale; Emmanuel S Buys; Rebecca M Sappington
Journal:  Neurobiol Dis       Date:  2018-09-10       Impact factor: 5.996

2.  Vascular tone pathway polymorphisms in relation to primary open-angle glaucoma.

Authors:  J H Kang; S J Loomis; B L Yaspan; J C Bailey; R N Weinreb; R K Lee; P R Lichter; D L Budenz; Y Liu; T Realini; D Gaasterland; T Gaasterland; D S Friedman; C A McCarty; S E Moroi; L Olson; J S Schuman; K Singh; D Vollrath; G Wollstein; D J Zack; M Brilliant; A J Sit; W G Christen; J Fingert; J P Forman; E S Buys; P Kraft; K Zhang; R R Allingham; M A Pericak-Vance; J E Richards; M A Hauser; J L Haines; J L Wiggs; L R Pasquale
Journal:  Eye (Lond)       Date:  2014-03-07       Impact factor: 3.775

3.  Vasodilatory effect of L-arginine on isolated rabbit and human posterior ciliary arteries in vitro and increased optic disc blood flow in vivo.

Authors:  Hideki Chuman; Takako Sugimoto; Nobuhisa Nao-I
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-10-23       Impact factor: 3.117

Review 4.  Vascular and autonomic dysregulation in primary open-angle glaucoma.

Authors:  Louis R Pasquale
Journal:  Curr Opin Ophthalmol       Date:  2016-03       Impact factor: 3.761

Review 5.  Genetics of primary open angle glaucoma.

Authors:  Mitsuko Takamoto; Makoto Araie
Journal:  Jpn J Ophthalmol       Date:  2013-11-21       Impact factor: 2.447

6.  Sex hormone levels and risk of primary open-angle glaucoma in postmenopausal women.

Authors:  Jae Hee Kang; Bernard A Rosner; Janey L Wiggs; Louis R Pasquale
Journal:  Menopause       Date:  2018-10       Impact factor: 2.953

Review 7.  Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension.

Authors:  Paul L Kaufman
Journal:  Expert Opin Pharmacother       Date:  2017-02-20       Impact factor: 3.889

Review 8.  Is Estrogen a Therapeutic Target for Glaucoma?

Authors:  Samantha S Dewundara; Janey L Wiggs; David A Sullivan; Louis R Pasquale
Journal:  Semin Ophthalmol       Date:  2016       Impact factor: 1.975

9.  Association of CAV1/CAV2 genomic variants with primary open-angle glaucoma overall and by gender and pattern of visual field loss.

Authors:  Stephanie J Loomis; Jae H Kang; Robert N Weinreb; Brian L Yaspan; Jessica N Cooke Bailey; Douglas Gaasterland; Terry Gaasterland; Richard K Lee; Paul R Lichter; Donald L Budenz; Yutao Liu; Tony Realini; David S Friedman; Catherine A McCarty; Sayoko E Moroi; Lana Olson; Joel S Schuman; Kuldev Singh; Douglas Vollrath; Gadi Wollstein; Donald J Zack; Murray Brilliant; Arthur J Sit; William G Christen; John Fingert; Peter Kraft; Kang Zhang; R Rand Allingham; Margaret A Pericak-Vance; Julia E Richards; Michael A Hauser; Jonathan L Haines; Louis R Pasquale; Janey L Wiggs
Journal:  Ophthalmology       Date:  2013-10-25       Impact factor: 12.079

10.  Pharmacological regulation of outflow resistance distal to Schlemm's canal.

Authors:  Fiona McDonnell; W Michael Dismuke; Darryl R Overby; W Daniel Stamer
Journal:  Am J Physiol Cell Physiol       Date:  2018-04-06       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.